Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tenapanor - Ardelyx

Next Previous
Drug Profile

Tenapanor - Ardelyx

Alternative Names: AZD-1722; AZD1722-hydrochloride; IBSRELA; Ibsrela; KHK-7791; PHOZEVEL; RDX-5791; Tenapanor hydrochloride; XPHOZAH

Latest Information Update: 27 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ardelyx
  • Developer Ardelyx; Knight Therapeutics; Kyowa Kirin; Shanghai Fosun Pharmaceutical
  • Class Benzylisoquinolines; Chlorinated hydrocarbons; Gastrokinetics; Heart failure therapies; Hyperphosphataemia therapies; Irritable bowel syndrome therapies; Small molecules; Sulfonamides; Urea compounds; Urologics
  • Mechanism of Action Sodium-hydrogen exchanger 3 inhibitors; TRPV1 protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hyperphosphataemia
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hyperphosphataemia; Irritable bowel syndrome
  • Phase II Renal failure
  • Discontinued Heart failure

Most Recent Events

  • 20 Feb 2024 Kyowa Kirin plans to launch Tenapanor (PHOZEVEL® ) for Hyperphosphataemia in Japan (PO)
  • 27 Nov 2023 Ardelyx initiates a phase I pharmacokinetic trial (In volunteers) in USA (PO) (NCT06203444)
  • 15 Nov 2023 Tenapanor - Ardelyx receives Orphan Drug status for Pediatric Hyperphosphataemia in USA
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top